EP0666923A4 - TARGET DELIVERY OF POLYNUCLEOTIDES OR OLIGONUCLEOTIDES TO CELLS. - Google Patents

TARGET DELIVERY OF POLYNUCLEOTIDES OR OLIGONUCLEOTIDES TO CELLS.

Info

Publication number
EP0666923A4
EP0666923A4 EP19920920863 EP92920863A EP0666923A4 EP 0666923 A4 EP0666923 A4 EP 0666923A4 EP 19920920863 EP19920920863 EP 19920920863 EP 92920863 A EP92920863 A EP 92920863A EP 0666923 A4 EP0666923 A4 EP 0666923A4
Authority
EP
European Patent Office
Prior art keywords
polynucleotides
oligonucleotides
cells
target delivery
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920920863
Other languages
German (de)
French (fr)
Other versions
EP0666923A1 (en
Inventor
George Y Wu
Catherine H Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of EP0666923A4 publication Critical patent/EP0666923A4/en
Publication of EP0666923A1 publication Critical patent/EP0666923A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP92920863A 1991-09-05 1992-09-04 Targeted delivery of poly- or oligonucleotides to cells Ceased EP0666923A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75508391A 1991-09-05 1991-09-05
US755083 1991-09-05
US78811991A 1991-11-04 1991-11-04
US788119 1991-11-04
US86400392A 1992-04-03 1992-04-03
US864003 1992-04-03
PCT/US1992/007339 WO1993004701A1 (en) 1991-09-05 1992-09-04 Targeted delivery of poly- or oligonucleotides to cells

Publications (2)

Publication Number Publication Date
EP0666923A4 true EP0666923A4 (en) 1995-01-20
EP0666923A1 EP0666923A1 (en) 1995-08-16

Family

ID=27419474

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92920863A Ceased EP0666923A1 (en) 1991-09-05 1992-09-04 Targeted delivery of poly- or oligonucleotides to cells

Country Status (6)

Country Link
EP (1) EP0666923A1 (en)
JP (1) JPH07500820A (en)
KR (1) KR100252547B1 (en)
AU (1) AU681997B2 (en)
CA (1) CA2116107A1 (en)
WO (1) WO1993004701A1 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
EP0681482B1 (en) * 1993-01-22 2005-12-07 University Research Corporation Localization of therapeutic agents
JPH08508645A (en) * 1993-04-05 1996-09-17 ユニバーシティ オブ コネティカット Targeted delivery of genes encoding antisense polyribonucleotides
EP0693939A1 (en) * 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4331011A1 (en) * 1993-09-13 1995-03-16 Bayer Ag C-branched oligomers that bind nucleic acids for therapy and diagnostics
DE4331012A1 (en) * 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
WO1995022618A1 (en) * 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
JPH09509329A (en) * 1994-05-13 1997-09-22 チロン ビアジーン，インコーポレイティド Compositions and methods targeting gene delivery vehicles
FR2721612B1 (en) * 1994-06-23 1996-08-09 Idm New oligoside derivatives, their preparation process and their applications.
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
DE4427980A1 (en) * 1994-08-08 1996-02-15 Bayer Ag Nucleic acid binding oligomers for therapy and diagnostics
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
CA2212682A1 (en) 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US6057431A (en) * 1995-03-31 2000-05-02 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
AU7727298A (en) * 1997-06-06 1998-12-21 Regents Of The University Of Michigan, The Neuregulin response element and uses therefor
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
CA2305341C (en) 1997-10-01 2009-01-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6197513B1 (en) 1998-02-11 2001-03-06 Pe Corporation PNA and DNA conjugates and methods for preparation thereof
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
DE19858005B4 (en) * 1998-12-16 2007-02-08 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Synthetic nucleic acid particle
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
ATE289630T1 (en) * 1999-09-09 2005-03-15 Curevac Gmbh TRANSFER OF MRNAS USING POLYCATIONIC COMPOUNDS
JP2004509604A (en) * 2000-03-28 2004-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド Modification of cell behavior by antisense modulation of mRNA processing
US20020115216A1 (en) * 2000-05-19 2002-08-22 Steer Clifford J. Composition for delivery of compounds to cells
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
KR20110140143A (en) 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
JP5060134B2 (en) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ Epitope of human cytotoxic T lymphocytes and its non-variable number of non-VNTR (non-variable number of nucleotide repeat sequences) of MUC-1
NL1027479C2 (en) * 2004-10-21 2006-05-01 Synvolux Ip B V Protection of biologically active molecules with the help of amphiphiles.
NZ560320A (en) 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US8664364B2 (en) 2007-01-24 2014-03-04 Carnegie Mellon University Optical biosensors
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2010096388A2 (en) 2009-02-18 2010-08-26 Carnegie Mellon University Quenched dendrimeric dyes for bright detection
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
CN108404123A (en) 2010-01-15 2018-08-17 康奈尔大学 The method for reducing intracellular protein level
AU2011207348A1 (en) 2010-01-21 2012-08-02 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
EP2577309B1 (en) 2010-05-25 2016-11-23 Carnegie Mellon University Targeted probes of cellular physiology
US9527924B2 (en) 2010-06-02 2016-12-27 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CA2823194A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
EP2831117B1 (en) 2012-03-29 2017-11-01 NovImmune SA Anti-tlr4 antibodies and uses thereof
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
CN105121467B (en) 2012-12-03 2019-07-05 诺夫免疫股份有限公司 Anti-CD47 antibodies and methods of use
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
JP2017531427A (en) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody and method of use thereof
JP6795505B2 (en) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Humanized CC chemokine receptor 4 (CCR4) antibody and its usage
CN107429075B (en) 2014-11-17 2022-11-01 卡内基梅隆大学 Activatable two-component photosensitizer
CA2967379A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
JP7033082B2 (en) 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド Detection of exosomes with surface markers
CN109310885B (en) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b targeting antibody-drug conjugates and methods of use thereof
SG11201900500TA (en) 2016-07-22 2019-02-27 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018048939A1 (en) 2016-09-06 2018-03-15 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
US11203646B2 (en) 2018-03-14 2021-12-21 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROTHENBERG, M. ET AL.: "Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 81, no. 20, 18 October 1989 (1989-10-18), BETHESDA, MD, USA, pages 39 - 44, XP000351436 *
See also references of WO9304701A1 *
WU, G. & WU, C.: "DELIVERY SYSTEMS FOR GENE THERAPY.", BIOTHERAPY (DORDR) 3 (1). 1991. 87-96 *
WU, G. ET AL.: "RECEPTOR-MEDIATED IN-VITRO GENE TRANSFORMATION BY A SOLUBLE DNA CARRIER SYSTEM.", J BIOL CHEM 262 (10). 1987. 4429-4432 *

Also Published As

Publication number Publication date
WO1993004701A1 (en) 1993-03-18
KR100252547B1 (en) 2000-09-01
JPH07500820A (en) 1995-01-26
EP0666923A1 (en) 1995-08-16
AU681997B2 (en) 1997-09-18
CA2116107A1 (en) 1993-03-18
AU2678092A (en) 1993-04-05

Similar Documents

Publication Publication Date Title
EP0666923A4 (en) TARGET DELIVERY OF POLYNUCLEOTIDES OR OLIGONUCLEOTIDES TO CELLS.
BR8907666A (en) DERIVATION OF PLURIPOTENTIAL EMBRYO CELL LINES FROM DOMESTIC ANIMALS
DE69219727D1 (en) Nucleic acid target generation
ITTO940572A0 (en) FERTILIZER PREPARATION SUITABLE FOR IMPROVING THE EXTRACTION OF PHOSPHORUS FOR PLANTS.
FR2603202B1 (en) NOE'S ARCHED TOY.
IT8905164A0 (en) ANGLE GEARBOX FOR AGRICULTURAL MACHINES.
MA23709A1 (en) cepheme crystalline addition salts with acids, processes for their preparation, medicaments containing them and their use
NO165271C (en) COVER PLATE FOR PROMOTING PLANT GROWTH.
FR2636501B3 (en) PLANT IRRIGATION SYSTEM
BR8900051A (en) AEROBIC CULTIVATION TANK
FI892132A7 (en) Prodrugs of 2',3'-didehydro-2',3'-dideoxynucleosides
IT8719367A0 (en) ORGANIC PHOSPHITES RESISTANT TO HYDROLYSIS AND PROCEDURE FOR THEIR PREPARATION.
FR2689271B1 (en) THREE-DIMENSIONAL ENERGY DISTRIBUTOR.
FR2595907B1 (en) ANIMAL MILKING FACILITY
IT1216056B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING THYMINE ALPHA 1.
FR2605041B3 (en) RECALL OR ASSISTANCE TORSION BAR.
IT8530671V0 (en) TRANSPARENT PLASTIC COVER FOR THE PROTECTION OF AGRICULTURAL CROPS, IN PARTICULAR ORCHARDS.
IT213428Z2 (en) WATER VAPOR STERILIZER PARTICULARLY FOR DENTAL USES.
IT8720001V0 (en) SYSTEM TO IRRIGATE FLAT OR LITTLE GROUNDS
FR2609388B1 (en) DENTAL ARCH ARCH INSERTS
IT213877Z2 (en) HIGHLY SIMPLE CONSTRUCTION HEATING BOILER.
IT9067465A0 (en) GREENHOUSE SHELTER FOR SINGLE PLANTINGS OR GROUPS OF A FEW UNITS.
FR2565962B1 (en) BIOLOGICAL WATER PURIFICATION PROCESS
GB8720381D0 (en) Hybridising probe to dna/rna target
IT8907001V0 (en) CONICAL TORQUE OF ANGLE TRANSFER FOR AGRICULTURAL MACHINES.

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20030306